SML0720

Methazolamide

≥98% (HPLC)

• Synonym(s): 5-Acetylimino-4-methyl-·2-1,3,4-thiadiazoline-2-sulfonamide, N-(4-Methyl-2-sulfamoyl-Δ²-1,3,4-thiadiazolin-5-ylidene) acetamide, L 584601, N-[5-(Aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
• Empirical Formula (Hill Notation): C₅H₈N₄O₃S₂
• CAS Number: 554-57-4
• Molecular Weight: 236.27
• EC Number: 209-066-7
• MDL number: MFCD00083416
• UNSPSC Code: 12352200
• PubChem Substance ID: 329825590
• NACRES: NA.77

Properties

• Assay: ≥98% (HPLC)
• form: powder
• storage condition: protect from light
• color: white to beige
• mp: 208 °C (dec.) (lit.)
• solubility: DMSO: 20 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: CN1N=C(S\C1=N\C(C)=O)S(N)(=O)=O
• InChI: 1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)/b7-4+
• InChI key: FLOSMHQXBMRNHR-QPJJXVBHSA-N
• Gene Information: human ... CA1(759) , CA2(760) , CA4(762) , CA7(766)

Description

Biochem/physiol Actions

Methazolamide has a plasma half-life of 14 hours in humans. Methazolamide has relatively good lipid solubility and low plasma protein binding ability. Thus, it diffuses into tissues and fluids much more readily than acetazolamide, another carbonic anhydrase inhibitor. Methazolamide has less side effects than acetazolamide.

Methazolamide is a cell-permeable and potent carbonic anhydrase (CA) inhibitor that is used in the treatment of glaucoma. Methazolamide is an insulin sensitizer that reduces hepatic glucose generation in animal models.

Other Notes

Light sensitive

Safety Information

• Pictograms: GHS08,GHS07
• Signal Word: Warning
• Hazard Statements: H302 + H312 + H332,H351
• Precautionary Statements: P202 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312 - P308 + P313
• Hazard Classifications: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Carc. 2
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3